Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342379 · ClinicalTrials.gov registry record · Phase 2
TH-302 in Combination With Bevacizumab for Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT02342379: Completed Phase 2 study of Glioblastoma, sponsored by The University of Texas Health Science Center at San Antonio.
NCT02342379 is a Phase 2 study of Glioblastoma that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 35 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02342379, a Phase 2 study of Glioblastoma, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
Dual center, single arm, two-stage, non-blinded, prospective study of combination therapy bevacizumab at 10mg/kg and TH-302 at 670mg/m2 every 2 weeks (6 week cycle) until disease progression.
Primary Outcome
Safety lab tests and adverse event assessment
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG TH-302
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Texas
- University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2015-05 |
| Est. Completion | 2019-12-04 |
| Phase | Phase 2 |
What the finished NCT02342379 record still lists
NCT02342379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02342379 reports a single indexed study location in Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT02342379 about?
NCT02342379 is a clinical study titled "TH-302 in Combination With Bevacizumab for Glioblastoma". Dual center, single arm, two-stage, non-blinded, prospective study of combination therapy bevacizumab at 10mg/kg and TH-302 at 670mg/m2 every 2 weeks (6 week cycle) until disease progression.
What is the current status of trial NCT02342379?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2015-05. Estimated completion is 2019-12-04.
What conditions does trial NCT02342379 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT02342379?
The interventions under investigation include: Bevacizumab (DRUG), TH-302 (DRUG).
Who is sponsoring clinical trial NCT02342379?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02342379 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02342379's enrollment target sits among peer trials
35 118th of 199 higher than 82 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia